Risk of Mortality, Fatal Infection, and Fatal Malignancy Related to Use of Anti-Tumor Necrosis Factor-α Biologics by Rheumatoid Arthritis Patients

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 3, 2012, Pages 223-233

  Thyagarajan, Veena ^a   Norman, Heather ^b   Alexander, Kimberly A ^c   Napalkov, Pavel ^c   Enger, Cheryl ^a  

^a OptumInsight (Formerly Ingenix i3 Drug Safety)   (United States)

^b OptumInsight   (United States)

^c GENENTECH INC   (United States)

Author keywords

Anti TNF therapy; Infection; Malignancy; Mortality; Rheumatoid Arthritis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BIOLOGICAL THERAPY; BREAST CANCER; BRONCHOPNEUMONIA; BRONCHUS CANCER; CANCER RISK; CHRONIC BRONCHITIS; COHORT ANALYSIS; DRUG EXPOSURE; DRUG FATALITY; DRUG MEGADOSE; DRUG USE; ENCEPHALITIS; ENCEPHALOMYELITIS; ENDOCARDITIS; FEMALE; GALLBLADDER CANCER; HUMAN; INCIDENCE; INFECTION; INFECTION RATE; INFECTION RISK; KIDNEY CANCER; LOW DRUG DOSE; LUNG CANCER; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; MYELITIS; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OSTEOMYELITIS; PANCREAS CANCER; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEPTICEMIA; STOMACH CANCER; STREPTOCOCCUS INFECTION; TONGUE CANCER; URINARY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84869124774     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.05.004     Document Type: Article

References (42)

1. Rheumatoid arthritis page National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases Website, Accessed December 8, 2010. http://www.niams.nih.gov/Health_Info/Rheumatic_Disease/default.asp.
2. Helmick C.G., Felson D.T., Lawrence R.C., Gabriel S., Hirsch R., Kwoh C.K., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008, 58(1):15-25. National Arthritis Data Workgroup.
3. Sokka T., Abelson B., Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008, 26(Suppl 51):S35-S61.
4. Myasoedova E., Davis J.M., Crowson C.S., Gabriel S.E. Epidemiology of rheumatoid arthritis: Rheumatoid arthritis and mortality. Curr Rheumatol Rep 2010, 12(5):379-385.
5. Gonzalez A., Maradit Kremers H., Crowson C.S., Nicola P.J., Davis J.M., Therneau T.M., et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007, 56(11):3583-3587.
6. Gabriel S.E., Crowson C.S., Kremers H.M., Doran M.F., Turesson C., O'Fallon W.M., et al. Survival in rheumatoid arthritis: A population-based analysis of trends over 40 years. Arthritis Rheum 2003, 48(1):54-58.
7. Mikuls T.R., Fay B.T., Michaud K., Sayles H., Thiele G.M., Caplan L., et al. Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: Results from the VARA registry. Rheumatology (Oxford) 2011, 50(1):101-109.
8. Radovits B.J., Fransen J., Al Shamma S., Eijsbouts A.M., van Riel P.L., Laan R.F. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010, 62(3):362-370.
9. Björnådal L., Baecklund E., Yin L., Granath F., Klareskog L., Ekbom A. Decreasing mortality in patients with rheumatoid arthritis: Results from a large population based cohort in Sweden, 1964-95. J Rheumatol 2002, 29(5):906-912.
10. Kvalvik A.G., Jones M.A., Symmons D.P. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 2000, 29:29-37.
11. Sihvonen S., Korpela M., Laippala P., Mustonen J., Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: A population-based study. Scand J Rheumatol 2004, 33(4):221-227.
12. Koivuniemi R., Paimela L., Suomalainen R., Piirainen H., Karesoja M., Helve T., et al. Causes of death in patients with rheumatoid arthritis autopsied during a 40-year period. Rheumatol Int 2008, 28(12):1245-1252.
13. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59(6):762-784.
14. Feldmann M., Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned?. Annu Rev Immunol 2001, 19:163-196.
15. Askling J., Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20(2):138-144.
16. Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl 2009, 82:S25-S32.
17. Schneeweiss S., Setoguchi S., Weinblatt M.E., Katz J.N., Avorn J., Sax P.E., et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007, 56(6):1754-1764.
18. Thompson A.E., Rieder S.W., Pope J.E. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials. Arthritis Rheum 2011, 63(6):1479-1485.
19. Galloway J.B., Hyrich K.L., Mercer L.K., Dixon W.G., Fu B., Ustianowski A.P., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011, 50(1):124-131.
20. Curtis J.R., Patkar N., Xie A., Martin C., Allison J.J., Saag M., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007, 56(4):1125-1133.
21. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52(11):3403-3412.
22. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295(19):2275-2285.
23. Bongartz T., Warren F.C., Mines D., Matteson E.L., Abrams K.R., Sutton A.J. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: A systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009, 68(7):1177-1183.
24. Askling J., van Vollenhoven R.F., Granath F., Raaschou P., Fored C.M., Baecklund E., et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment?. Arthritis Rheum 2009, 60(11):3180-3189.
25. Wolfe F., Michaud K. Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50(6):1740-1751.
26. Askling J., Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20(3):334-339.
27. Brown S.L., Greene M.H., Gershon S.K., Edwards E.T., Braun M.M. Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the food and drug administration. Arthritis Rheum 2002, 46(12):3151-3158.
28. Katoulis A.C., Kanelleas A., Zambacos G., Panayiotides I., Stavrianeas N.G. Development of two primary malignant melanomas after treatment with adalimumab: A case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation. Dermatology 2010, 221(1):9-12.
29. Carmona L., Descalzo M.A., Perez-Pampin E., Ruiz-Montesinos D., Erra A., Cobo T., et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007, 66(7):880-885.
30. Jacobsson L.T., Turesson C., Nilsson J.A., Petersson I.F., Lindqvist E., Saxne T., et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66(5):670-675.
31. Lunt M., Watson K.D., Dixon W.G., Symmons D.P., Hyrich K.L., et al. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2010, 62(11):3145-3153. British Society for Rheumatology Biologics Register.
32. National Death Index, Accessed May 20, 2011. http://www.cdc.gov/nchs/ndi.htm.
33. Report on Carcinogens (RoC) National Toxicology Program, Department of Health and Human Services, 11th Edition, Accessed December 21, 2010. http://ntp.niehs.nih.gov/.
34. Humira (adalimumab) [product insert]. Abbott Laboratories Revised Sept. 2010.
35. Enbrel (etanercept) [product insert]. Immunex Corporations Revised Sept. 2010.
36. Remicade (infliximab) [product insert]. Centocor Ortho Biotech Inc Revised Nov. 2009.
37. Rothman K.J. Epidemiology: An introduction 2002, 134. Oxford University Press, New York, NY.
38. Compressed mortality file 1999-2007. CDC WONDER On-line Database, compiled from Compressed Mortality File 1999-2007, series 20, 2M, 2010 Centers for Disease Control and Prevention, National Center for Health Statistics, Accessed August 2, 2011. http://wonder.cdc.gov/cmf-icd10.html.
39. Leombruno J.P., Einarson T.R., Keystone E.C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analysis of serious adverse events. Ann Rheum Dis 2009, 68(7):1136-1145.
40. Fillenbaum G.G., Burchett B.M., Blazer D.G. Identifying a national death index match. Am J Epidemiol 2009, 170(4):515-518.
41. Doody M.M., Hayes H.M., Bilgrad R. Comparability of national death index plus and standard procedures for determining causes of death in epidemiologic studies. Ann Epidemiol 2001, 11(1):46-50.
42. Puolakka K., Kautiainen H., Pohjolainen T., Virta L. No increased mortality in incident cases of rheumatoid arthritis during the new millennium. Ann Rheum Dis 2010, 69:2057-2058.